

Press Release

Cellzome Announces Achievement of First Milestone in Epigenetics Collaboration with GSK

Heidelberg, Germany and Cambridge, UK- 8th December 2010 – Cellzome announced today that it has successfully achieved the first milestone in its epigenetics alliance with GlaxoSmithKline. The achievement of the milestone triggers a payment from GlaxoSmithKline of an undisclosed amount.

The strategic collaboration was announced in March this year and gives GSK exclusive access to Cellzome's proprietary *Episphere*[™] technology in the emerging field of epigenetics as applied to immuno-inflammatory disease. Under the terms of the agreement, the companies work together using Cellzome's *Episphere*[™] technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes. The companies share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialisation.

Tim Edwards, CEO of Cellzome, said: "We have made an excellent start in this collaboration with GSK. It is only by working with the native proteins from relevant tissue sources that we can really understand these protein complexes and make progress in this exciting area of drug discovery."

- ends -

For more information please contact:

Cellzome:

Tim Edwards
Chief Executive Officer
Tel: +49 (0) 6221-137 57-100
press@cellzome.com

Media contact:

MHP Communications
John Olsen
Tel: +44 (0) 20 3128 8100

About Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Our pipeline of small-molecule therapeutics is driven by *Kinobeads*[™], a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called *Episphere*[™] to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Cellzome has two strategic alliances with GSK to discover and develop drugs to treat inflammatory diseases, the first in the field of kinase-targeted therapeutics and the second in the field of epigenetics.

Cellzome's holding company is domiciled in the US and it employs about 95 people at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: www.cellzome.com